SCHEMBL24143548

SCHEMBL24143548

NCCc1cn(Cc2ccc(F)cc2)c2cc(-c3ccncc3)ccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NFATC1 O95644 1/20 0.50
▸ GSK3B P49841 1/20 0.50
▸ DYRK1A Q13627 1/20 0.50
▸ SERPINE1 P05121 1/20 0.47
▸ CYP19A1 P11511 2/20 0.44
▸ KDR P35968 4/20 0.43
▸ EGFR P00533 3/20 0.43
▸ IGF1R P08069 3/20 0.43
▸ FLT4 P35916 3/20 0.43
▸ NR1D1 P20393 5/20 0.43
▸ HTR6 P50406 1/20 0.41
▸ MAOB P27338 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ ALOX12 P18054 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24144070 0.88 HTR6 (0.54) DYRK1ASERPINE1CYP19A1KDREGFR
SCHEMBL24144502 0.88 CYP19A1 (0.47) GSK3BCYP19A1KDREGFRIGF1R
SCHEMBL24143540 0.88 NR1D1 (0.42) NFATC1GSK3BDYRK1ASERPINE1NR1D1
SCHEMBL24143557 0.84 CYP19A1 (0.45) CYP19A1KDREGFRIGF1RFLT4
SCHEMBL24144386 0.84 LMNA (0.45) DYRK1ASERPINE1KDREGFRIGF1R
SCHEMBL24144642 0.81 NR1D1 (0.49) NFATC1GSK3BDYRK1ASERPINE1CYP19A1
SCHEMBL24144290 0.81 HTR6 (0.41) GSK3BDYRK1ASERPINE1CYP19A1KDR
SCHEMBL24144383 0.81 CYP19A1 (0.49) DYRK1ASERPINE1CYP19A1KDREGFR
SCHEMBL24143743 0.81 NR1D1 (0.50) CYP19A1NR1D1HTR6
SCHEMBL24144465 0.79 NR1D1 (0.48) NR1D1HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021263278-A1 REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS THE SCRIPPS RESEARCH INSTITUTE (US) 2021-12-30 — — WO disclosed
Send feedback